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ABSTRACT
Niraparib is an oral, potent, highly selective
poly-ADP ribose polymerase 1 (PARP1) and
PARP2 inhibitor. In most developed countries,
it is approved as a maintenance treatment for
epithelial ovarian, fallopian tube, or primary
peritoneal cancer in patients with complete or
partial response to platinum-based therapy.
These approvals are based on results of ran-
domised, double-blind, placebo-controlled tri-
als, particularly the NOVA trial and more
recently the PRIMA trial. In this comprehensive
review, we delve into the scientific basis of PARP
inhibition, discussing both preclinical and
clinical data which have led to the current
approval status of niraparib. We also discuss
ongoing trials and biological rationale of com-
bination treatments involving niraparib, with
particular focus on antiangiogenic drugs,
immune checkpoint inhibitors and cyclic GMP-
AMP synthase stimulator of interferon genes
(cGAS/STING) pathway. In addition, we reflect
on potential strategies and challenges of utilis-
ing current biomarkers for treatment selection
of patients to ensure maximal benefit.
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Key Summary Points
Niraparib is a potent and highly selective
poly-ADP ribose polymerase (PARP)
inhibitor.
It is approved as a maintenance treatment
for epithelial ovarian cancer which has
demonstrated response to platinum
chemotherapy.
We review the scientific basis of PARP
inhibition, chronologically detailing
preclinical and clinical data which have
led to the approvals to date.
We also discuss ongoing trials and the
biological rationale for combination
treatments, with a focus on the cGAS/
stimulator of interferon genes (STING)
pathway and immune checkpoint
inhibitors.
The review also highlights practical
challenges faced by clinicians, such as
limitations of current strategies in
defining biomarkers, particularly with
regard to homologous recombination
deficiency status.
INTRODUCTION
DNA damage can occur in a range of different
ways through a variety of endogenous and
exogenous stressors. Because of the diversity of
lesions, a number of complex, sophisticated
repair pathways have evolved which work syn-
ergistically to repair DNA damage. These
include base excision repair (BER), nucleotide
excision repair and mismatch repair for single-
strand breaks (SSB), and homologous recombi-
nation (HR) or non-homologous end-joining
(NHEJ) for repair of double-strand breaks (DSBs)
[1].
The family of poly-ADP ribose polymerases
(PARPs) are enzymes which mediate repair of
DNA SSBs primarily through BER. PARP1, the
founding and most abundant family member,
senses SSBs and binds to DNA at the site of
damage. Upon binding, it catalyses the transfer
of ADP-ribose units to many proteins, including
PARP1 itself, to form long poly-ADP ribose
(PAR) chains, a process known as poly-ADP-ri-
bosylation (PARylation). The auto-PARylation
of PARP1 triggers its release from the site of
damage, enabling DNA repair factors, which
have been recruited by the PAR chains, to
localise to the lesion [2]. The majority of PARP-
dependent repair activity is through PARP1,





Simultaneous inhibition of PARP1 and PARP2
results in persistence of SSBs. There is evidence
to suggest that this is due not only to inhibition
of the catalytic repair of SSB induced by PARP1,
but also to PARP1 trapping [4]. PARP inhibitors
(PARPi) block the synthesis of PAR chains,
thereby preventing autoPARylation of PARP1
and its release from the site of DNA damage.
The trapped PARP1 prevents repair of SSBs,
allowing progression to replication fork collapse
and formation of DNA DSBs. A schematic of the
mechanism of action of PARPi is shown in
Fig. 1.
This results in a heavy reliance on DSB repair
pathways such as HR. PARP inhibition in
patients with a defective HR pathway can
therefore result in gross genomic instability and
ultimately cell death by apoptosis. BRCA1 and
BRCA2 are key proteins involved in HR; there-
fore, in theory, PARP inhibition should be
selectively potent against cells which have
biallelic BRCA1 or BRCA2 deficiency. Thus,
knockout of either BRCA or PARP alone is
associated with cell viability, while simultane-
ous knockout of both genes results in cell death,
a concept known as ‘synthetic lethality’ [5].
There are many other genes that are also crucial
for HR and therefore have a synthetic lethal
interaction with PARP, including FANC, ATM,
CHEK2, MRE11A and RAD51 [6]. Many sporadic
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cancers harbour disruption of these genes, and
the resulting homologous recombination defi-
ciency (HRD) can therefore serve as a predictive
biomarker for sensitivity to PARP inhibition.
This article aims to provide a comprehensive
review of niraparib, covering the scientific basis
of PARP inhibition, discussing both preclinical
and clinical data which have led to the current
approval status of the drug. The review is based
on previously conducted studies and does not
contain any studies with human participants or
animals performed by any of the authors.
DEVELOPMENT OF NIRAPARIB
Niraparib is an oral, potent, highly selective
PARP1 and PARP2 inhibitor. Its discovery as the
compound 2-7-2H-indazole-7-carboxamide 56
(or MK-4827) was first reported in 2009 [7].
Jones et al. assessed the activity of niraparib
in vitro using an assay that measures the
amount of PAR chains formed in cells as a result
of DNA damage induced by hydrogen peroxide.
Niraparib was demonstrated to have excellent
Fig. 1 Mechanism of action of PARP inhibitors. In the
presence of base excision repair and homologous recom-
bination deficiency, double-strand break accumulation
occurs which eventually leads to cell death. BER base
excision repair, HRD homologous recombination defi-
ciency, SSB single-strand break, DSB double-strand break







IC50 half-maximal inhibitory concentration
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potency against PARP1 and PARP2, with half-
maximal inhibitory concentrations (IC50) of 3.8
and 2.1 nM, respectively, and at least 100-fold
selectivity over other members of the PARP
family (Table 1).
In vitro inhibition of proliferation of BRCA
mutated cancer cell lines was demonstrated,
with 50% cytotoxic concentration (CC50) of
18 nM in BRCA1-deficient cells and CC50 of
90 nM in BRCA2-deficient cells. Normal human
prostate and mammary epithelial cells were
resistant, with anti-proliferative effects seen at
micromolar concentrations, indicating selective
cytotoxicity for BRCA mutant cancer cells
compared to surrounding tissue [7]. In vivo
activity of niraparib on BRCA1 mutant cells was
assessed using mice models with implanted
human mammary adenocarcinoma cells that
had been silenced for BRCA1 [8]. At a dose of
80 mg/kg niraparib, significant inhibition of
tumour growth was observed after only 1–-
2 weeks of treatment, and continuous daily
dosing for[4 weeks resulted in complete and
sustained tumour regression. Activity against
BRCA2-deficient cells was assessed using a pan-
creatic cancer cell xenograft model. At the same
dose (80 mg/kg niraparib), approximately 60%
inhibition of tumour growth was observed after
2 weeks. In both cases, it was considered well
tolerated, with\ 10% reduction in body
weight.
Penetration of the blood–brain barrier has
also been assessed in the preclinical setting [9].
Pharmacokinetic studies were conducted in
germline BRCA mutant intracranial xenograft
models, and concentration–time profiles of
niraparib in the brain were similar to those in
plasma, with a mean brain-to-plasma
concentration ratio of 0.85–0.99 of the brain
Tmax. Clinical activity in the brain was also
assessed using a xenograft model with BRCA
mutant pancreatic tumour cells implanted
either subcutaneously or intracranially. Tumour
growth inhibition values at different doses of
niraparib are shown in Table 2. The data sup-
port an intracranial anti-tumour effect and
suggest that niraparib can effectively penetrate
the central nervous system to exert a therapeu-
tic benefit.
PHASE 1 TRIAL
In 2013, the results were published for a first-in-
human study of niraparib in patients with solid
organ tumours across three sites, one in the UK
and two in the USA [6]. One hundred patients
in total were enrolled, 49 of whom had ovarian
or primary peritoneal cancer, and 20 of whom
had germline BRCA mutations and were evalu-
able radiologically. The proportion of patients
achieving a RECIST [Response Evaluation Cri-
teria In Solid Tumors] partial response (PR) was
highest in those with BRCA mutated platinum-
sensitive disease, as demonstrated in Table 1.
The data suggest that both BRCA deficiency and
platinum sensitivity can serve as predictive
biomarkers for response to niraparib. The anti-
tumour activity seen amongst patients with
BRCA wild-type (BRCAwt) disease was felt to
potentially reflect HRD due to somatic silencing
of key genes (Table 3).
In terms of safety, the study demonstrated
good tolerance of niraparib up to the recom-
mended phase 2 dose of 300 mg/day. Non-
haematological toxicities such as nausea and









15 mg/kg 13 55
30 mg/kg 49 56
45 mg/kg 54 83
Table 3 Objective response rate in patients with ovarian
and primary peritoneal cancer to niraparib treatment by
BRCA mutation and platinum status
Objective response rate (n/total, %)
BRCA mutated BRCA wild-type
Platinum-sensitive 5/10 (50%) 1/3 (33%)
Platinum-resistant 3/9 (33%) 1/19 (5%)
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fatigue were rated as mild to moderate and were
felt to be manageable. Haematological toxicity
seemed to be dose-dependent, with anaemia
being most common and reaching grade 3 or
worse in 10% of patients. Thrombocytopenia
was less common, but grade 4 thrombocytope-
nia was dose-limiting at 400 mg/day. Neu-
tropenia was the least common, affecting 24%
of patients and reaching grade 3 in 4% of
patients at doses of 300 or 400 mg. In general,
myelosuppression was self-limiting and
resolved with treatment breaks or dose reduc-
tions. The study concluded that overall, nira-
parib was well tolerated and demonstrated
promising anti-tumour activity in both BRCA
mutated and sporadic solid organ cancers.
NOVA: THE FIRST THERAPEUTIC
TRIAL FOR NIRAPARIB
On the basis of these findings, a phase 3 ran-
domised controlled trial designed to further
evaluate efficacy of niraparib was undertaken.
This was the pivotal phase 3 NOVA trial [10].
Eligibility criteria incorporated the findings of
the phase 1 study, stipulating that patients must
have completed their last dose of platinum-
based therapy no more than 8 weeks prior to
enrolment and must have demonstrated sensi-
tivity to the penultimate platinum treatment
regimen defined as a PR or CR for at least
6 months. BRCA mutation and HR status were
not a feature of the inclusion criteria; however,
patients were stratified according to the pres-
ence or absence of a germline BRCA mutation.
Given there were some patients with sporadic
ovarian cancer who also responded to niraparib
in the phase 1 study, tumour samples from
patients lacking a germline BRCA mutation
were analysed for the presence of another
mutational process causing HRD. The Myriad
Genetics myChoice assay was used to detect
these processes (discussed later). The study
design is shown in Fig. 2.
The trial demonstrated a significant
improvement in progression-free survival (PFS)
in the niraparib group compared to placebo
across all three populations, with HR of 0.27
(95% CI 0.17–0.41) in the germline BRCA
mutation (gBRCAmut) cohort, 0.45 (95% CI
0.34–0.61) in the non-gBRCAmut cohort and
0.38 (95% CI 0.24–0.59) in the HRD subgroup of
the non-gBRCA cohort. Exploratory analyses
performed on the HRD subgroup to assess
whether somatic BRCA mutations were driving
the observed benefit from niraparib showed a
similar result in the somatic BRCAm group as
the gBRCA cohort, HR 0.27 (95% CI 0.08–0.9),
while those with BRCAwt in the HRD subgroup
benefitted less (HR 0.38; 95% CI 0.23–0.63). The
group which benefitted the least was the HR-
proficient (HRP) subgroup (HR 0.58, 95% CI
0.36–0.92). However, even in this group,
approximately 20% of the patients had a long-
term benefit ([ 18 months) from niraparib. On
the basis of these findings, niraparib was gran-
ted global approval for the maintenance treat-
ment of recurrent ovarian cancer regardless of
HR or BRCA status, the first in its class to be
licensed in this setting.
An updated analysis of the NOVA trial [11]
was presented in the Society for Gynaecologic
Oncology (SGO) Conference in 2021 and sug-
gested an increase in median overall survival
(OS) by 9.7 months in the BRCA-mutated pop-
ulation receiving niraparib, while no difference
was seen in patients with non-germline-BRCA
mutations. This needs to be interpreted in the
context that OS was a secondary end point, and
the study was not appropriately powered to
demonstrate this.
Some of the most common adverse events of
niraparib include anaemia, neutropenia,
thrombocytopenia, nausea and fatigue. These
have also been seen in other phase 3 trials of
PARP inhibitors used in the maintenance set-
ting, such as olaparib and rucaparib. Within the
constraints of cross-trial comparisons, severe
haematological toxicities are more common in
niraparib (25%) than in rucaparib and olaparib
(19% each) [12].
The updated analysis revealed that
myelodysplastic syndrome or acute myeloid
leukemia (MDS/AML) was reported in 3.5%
patients treated with niraparib, with slightly
higher incidence in those with gBRCAm. It also
showed that the most common adverse events
(myelosuppression, nausea, fatigue, insomnia)
seemed to occur mostly in the first few months,
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with dose reductions being highest in month 1
and declining every month thereafter, high-
lighting the importance of appropriate dose
reduction according to toxicity criteria.
In light of the toxicity profile, a retrospective
analysis was carried out to identify parameters
that could predict dose reductions. Patients
with a body weight of\77 kg and platelet
count of\ 150 9 109/L were found to have
increased risk of treatment-emergent adverse
events and haematological toxicity; therefore, a
starting dose of 200 mg has been recommended
for patients with either of these parameters.
Clinical efficacy did not appear to be affected by
dose modifications in patients with dose
reduction [13].
Importantly, quality-of-life measurements
for patients receiving niraparib were similar to
those for patients receiving placebo, which is
particularly relevant in the maintenance setting
[14].
PRIMA TRIAL: MOVING NIRAPARIB
TO THE FIRST-LINE MAINTENANCE
SETTING
While the NOVA study looked at patients with
recurrent, heavily pretreated ovarian cancer, the
PRIMA study was a phase 3 trial evaluating
niraparib in the front-line setting in newly
diagnosed ovarian cancer. [15] The study design
is shown in Fig. 3.
The primary end point was median PFS and a
significant improvement was demonstrated in
both the overall population and the HRD sub-
group (HR 0.62; 95% CI 0.5–0.76 in overall
population and 0.43; 95% CI 0.31–0.59 in the
HRD group).
Exploratory analyses performed on the HRD
subgroup suggested that there was significant
benefit in those with BRCA mutations (HR 0.40,
95% CI 0.27–0.62) as well as in those without
BRCA mutations (HR 0.50, 95% CI 0.31–0.83).
Overall, again, the smallest margin of benefit
was observed in those with HRP disease (HR
Fig. 2 NOVA study design. CR complete response, PR
partial response, PFS progression-free survival, RECIST
Response Evaluation Criteria in Solid Tumours,
gBRCAmut = germline BRCA mutation, non-gBRCAmut
= No germline BRCA mutation
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0.68, 95% CI 0.49–0.94). However, it is impor-
tant to note that the study was powered only for
the predefined primary analysis population,
which was the overall study population and the
HRD subgroup.
In comparison to other trials of up-front
PARP inhibitor maintenance (for example the
SOLO-1 trial of olaparib), the PRIMA study
population included a high proportion of high-
risk patients (Table 4), with 67% requiring
neoadjuvant chemotherapy, 23% with residual
disease after primary de-bulking surgery and
31% with only a PR to platinum-based
chemotherapy.
PRIMA concluded that niraparib mainte-
nance after first-line platinum-based
chemotherapy can extend benefit to all
patients, with lower sensitivity amongst the
HRP population. The results of the study formed
the evidence basis for approval of niraparib as
the only oral, once-daily PARPi as monotherapy
maintenance treatment for women with first-
line platinum-responsive advanced ovarian
cancer, regardless of biomarker status, in both
the USA and EU, and more recently the United
Kingdom (Fig. 4).
QUADRA TRIAL: INVESTIGATING
THE ROLE OF PARPI
AS MONOTHERAPY IN A HEAVILY
PRETREATED SETTING
While NOVA and PRIMA looked at niraparib as
maintenance therapy, QUADRA was a
Fig. 3 PRIMA study design. CR complete response, PR partial response, PFS progression-free survival, RECIST Response
Evaluation Criteria in Solid Tumours, OD once daily, Plt platelets
Table 4 High-risk features for patients with newly diag-
nosed ovarian cancer
Inoperable FIGO stage III disease
Suboptimally debulked ([ 1 cm) stage III disease
Stage IV disease
Receipt of neoadjuvant chemotherapy
Partial response to first-line platinum-based
chemotherapy
FIGO International Federation of Gynecology and
Obstetrics
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multicentre, single-arm phase 2 study which
investigated niraparib as a treatment line in
heavily pretreated patients with ovarian cancer
(C 3 lines of chemotherapy) [16]. Unlike NOVA
or PRIMA, QUADRA initially did not exclude
platinum-resistant or platinum-refractory dis-
ease; however, the eligibility criteria were sub-
sequently amended to restrict enrolment to
those with a response to first-line platinum-
based therapy of[ 6 months. Thirty-three per-
cent of the 463 patients enrolled were platinum-
resistant (platinum-free interval of 1–6 months
after most recent platinum-based therapy) and
35% platinum-refractory (platinum-free inter-
val\ 28 days). The study met its primary end
point, with 28% of the primary efficacy popu-
lation (47 patients with platinum-sensitive HRD
tumours who had received 3–4 lines of therapy)
achieving an overall response. Subgroup analy-
ses (for which the study was not powered)
demonstrated a hierarchical spectrum of benefit
based on biomarker and platinum status, the
results of which are shown in Fig. 4. The pattern
demonstrated suggests that BRCA mutation is
most predictive of a response to niraparib, even
more so than platinum sensitivity. The data for
median OS support this, with OS of 26 months
in the BRCAm population, 19 months in the
HRD population and 15.5 months in the HRP
population.
On the basis of QUADRA, the Food and Drug
Administration (FDA) approved niraparib as
monotherapy for patients with advanced ovar-
ian, fallopian tube or primary peritoneal cancer
who have had C 3 previous lines of treatment
and whose cancer is HRD-positive. Niraparib is
not currently indicated for this setting in the
UK or EU. A timeline of approvals for niraparib




The results from the three monotherapy nira-
parib trials indicate a clear hierarchy of sensi-
tivity, with the BRCA mutated cancers standing
to benefit the most and the HRP cancers
Fig. 4 QUADRA trial profile and overall response rates by HRD and platinum status. Platinum Res/Ref platinum
chemotherapy-resistant or -refractory, PARPi PARP inhibitor
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benefitting the least. The fact that all three trials
demonstrated some degree of benefit for
patients with HRP tumours may reflect a limi-
tation of the HRD assay used in distinguishing
genuine HR deficiency and proficiency. The
assay used in all three trials was the Myriad
Genetics myChoice test. This is a next-genera-
tion sequencing (NGS) test that combines
identification of germline or somatic BRCA1 or
BRCA2 variants with quantification of genomic
instability of the tumour [15]. Rather than
detecting inactivation of specific genes in the
HR repair pathway, the idea is to quantify
chromosomal abnormalities indicative of HRD
irrespective of the specific cause, a so called
‘genomic scar’. This genomic instability is
measured on the basis of loss of heterozygosity
(LOH), telomeric allelic imbalance (TAI) and
large-scale state transitions (LSTs). LOH is a
feature of many cancers, describing the second
hit to a tumour suppressor gene that already has
one defective allele. TAI and LSTs are both fea-
tures of HRD cells with TAI resulting from
attempts to repair DNA DSBs using the error-
prone NHEJ pathway and LSTs describing large
chromosomal breaks. These three biomarkers
are then used to generate a genomic instability
score (GIS) with HR deficiency being defined by
a score of greater than or equal to 42 or presence
of a BRCA mutation [17]. Another commercially
available genomic scar test is the Founda-
tionOne assay, which uses NGS to determine
percentage of genomic LOH, with ‘LOH-high’
indicating HRD positivity.
According to European Society for Medical
Oncology (ESMO) recommendations [18], HRD
tests which incorporate scores of allelic imbal-
ance (GIS or LOH) can identify a subgroup of
BRCAwt, platinum-sensitive cancers that derive
a greater magnitude of benefit from PARPi
therapy in some settings. However, the clinical
utility of these tests is limited by their inability
to consistently identify a BRCAwt subgroup that
derives no benefit from PARPi [18]. Thus, the
positive results seen amongst the so-called HRP
population in the niraparib monotherapy trials
throws into question the efficacy of the HRD
test and it is likely that there is some degree of
error with a proportion of BRCAwt patients
being incorrectly labelled as HRP (or HRD-neg-
ative). In addition, it is important to note that
these commercial HRD tests have been devel-
oped and validated by trials which have largely
specified platinum-sensitivity as an inclusion
criterion. This will inevitably have led to a
potential selection bias in the context of the
treatment-naı̈ve or platinum-refractory or plat-
inum-resistant patient, creating an area of large
unmet clinical need. Finally, the HRD assays
currently available do not provide a current
estimate of HRD status, being valid only for the
time at which the sample was obtained [18].
Thus, further work is needed to optimise testing
Fig. 5 Key dates for the FDA, EMA and NICE approvals for niraparib. FDA Food and Drug Administration, EMA
European Medicines Agency, NICE National Institute for Health and Care Excellence
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to provide an accurate and real-time estimate of
HR status.
The distinction of HRD and HRP is becoming
more crucial going forward going forward as the
treatment pathways for these two subgroups of
patients are likely to diverge. The challenge will
be to develop ways of enhancing the innate
sensitivity of those with HRD disease and to
overcome the innate resistance of those with
HRP disease. Combination therapy offers a
means of achieving this and several combina-
tions with different targeted therapies are under
investigation.
COMBINATION THERAPIES
Ovarian cancer is one of the most genomically
complex of all solid tumours. The heterogeneity
of ovarian cancer means that it is unlikely to be
cured with single-agent therapy. Combination
therapy is more likely to yield greater activity
with longer duration, as the disease is likely to
recur with potentially new resistance mecha-
nisms. The genomic complexity, alongside
intra-tumoural heterogeneity, has led clinicians
to explore different angles to develop the most
effective combination treatments alongside
PARPi.
Bevacizumab
The lymph-angiogenic tumour microenviron-
ment is an important element that has been a
target for modulation in ovarian cancer.
Bevacizumab, an anti-vascular epithelial
growth factor monoclonal antibody, has been
licensed as first-line therapy alongside
chemotherapy for advanced ovarian cancer for
some time. The evidence for its use came from
two large phase 3 randomised trials: GOG 0218
[19] and ICON7 [20]. Both studies demonstrated
a significant improvement in PFS with mainte-
nance bevacizumab versus placebo after plat-
inum-based chemotherapy, although this
improvement did not extend to OS, with the
exception of those with high-risk disease in the
ICON7 trial.
Vascular epithelial growth factor (VEGF) has
been demonstrated to promote HR by
contributing to the expression and function of
RAD51, an essential enzyme in the HR pathway
[21]. Inhibition of VEGF therefore leads to
defective HR and could theoretically sensitize
tumours to PARP inhibition, providing a ratio-
nale for this combination.
The phase 3 PAOLA-1 study randomised
patients with newly diagnosed platinum-sensi-
tive ovarian cancer to maintenance olaparib
plus bevacizumab versus placebo plus beva-
cizumab [22]. A clear benefit was seen in the
olaparib arm overall (HR 0.59, 95% CI
0.49–0.72) and in the BRCAm subgroup (HR
0.31; 95% CI 0.2–0.47). The benefit of mainte-
nance olaparib plus bevacizumab was clearly
seen in HRD-positive tumours including BRCA
mutations (HR 0.33, 95% CI 0.25–0.45) and also
in those with HRD-positive tumours without
BRCA mutations (HR 0.43, 95% CI 0.28–0.66).
Once again, those with HRP tumours or HR
status unknown derived the smallest margin of
benefit (HR of 0.92, 95% CI 0.71–1.17).
The phase 2 AVANOVA trial [23] randomised
patients with platinum-sensitive, heavily pre-
treated recurrent ovarian cancer to niraparib
alone or niraparib plus bevacizumab as a treat-
ment line. Results showed a median PFS of
11.9 months with the combination of nira-
parib/bevacizumab versus 5.5 months with sin-
gle-agent niraparib (adjusted HR 0.35; 95% CI
0.21–0.57). This improvement was seen regard-
less of HRD positivity (HR 0.38, 95% CI
0.20–0.72) or negativity (HR 0.40, 95% CI
0.19–0.85). These results led investigators to
further evaluate this combination and move it
to the front-line setting with the OVARIO study
[24].
OVARIO is a phase 2, single-arm study of
maintenance niraparib plus bevacizumab in a
similar population as PAOLA-1: patients with
advanced ovarian cancer who have responded
to first-line platinum chemotherapy with beva-
cizumab. Preliminary results were recently pre-
sented at the SGO conference 2021 and
demonstrated 18-month PFS rates of 62% in the
overall population, 76% amongst the HRD
patients and 47% amongst the HRP patients. No
new safety signals were generated, and the
researchers concluded that the combination is
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safe and continues to prolong PFS for a majority
of patients.
Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) have rev-
olutionised the treatment of multiple solid
tumours. At the time of writing, ICIs have not
achieved comparable success in epithelial ovar-
ian cancer, particularly in the context of
monotherapy [25]. Nevertheless, we postulate
that the combination of PARP inhibitors and
immune checkpoint inhibitors is a biologically
sound and synergistic treatment strategy.
To explore this potential synergy in detail,
we need to review the cGAS/STING pathway
which underscores the immunomodulatory
effects of PARP inhibitors [26]. The cGAS–c-
GAMP–STING pathway is activated when
cytosolic DNA is sensed by cyclic GMP-AMP
synthase (cGAS). The mechanisms by which
this cytosolic DNA accumulates are not fully
understood, but include chromosome instabil-
ity, DNA damage and oncosuppressor gene
mutation or deletion in tumour cells [27].
PARP1 trapping induced by PARPi has also been
proposed to generate cytosolic dsDNA and thus
contribute to activation of this innate immune
signalling pathway [28].
Upon sensing cytosolic DNA, cGAS catalyses
the formation of cyclic GMP, which in turn
leads to activation of stimulator of interferon
genes (STING). This results in recruitment of
TANK-binding kinase 1 (TBK1), followed by
phosphorylation and activation of IRF3, causing
the activation of type I IFN transcription [29].
The upregulation of type 1 interferons and
other pro-inflammatory cytokines leads to
tumour suppressive effects. Figure 6 provides a
schematic of the activation of the cGAS/STING
pathway by PARP inhibition.
In addition, cancer cells can induce activa-
tion of cGAS-STING signalling in nearby den-
dritic cells. There are several main hypotheses
[30] to explain this phenomenon:
1. Tumour-derived cGAMP is secreted into the
extracellular space and imported into host
immune cells through the folate transporter
SLC19A1 and direct activation of STING.
2. Tumour-derived DNA is released and trans-
ported into dendritic cell cytosol through
unestablished mechanisms, and sensed by
c-GAS STING pathway (e.g., indirect exo-
some-mediated DNA transfer [31]).
3. cGAMP transfer through gap junctions
between cancer and immune cells [32].
Either way, the resultant production of type
1 interferons in the tumour microenvironment
promotes dendritic cell maturation and cross-
presentation of tumour-associated antigens to
CD8? T cells, leading to anti-tumour responses
[29].
The combination of PARPi with an immune
checkpoint inhibitor is a potent strategy for
several reasons. PARPi have been shown to
enhance PD-L1 expression on tumour cells both
in vitro and in vivo, an effect which has been
observed with both BRCA-deficient and BRCA-
proficient cell lines [33]. In theory, this could
lead to an upregulation of the inhibitory PD-1/
PD-L1 axis which would dampen cytotoxic T
cell response. Combining PD-1/PD-L1 inhibi-
tion with PARP inhibition would mitigate this
mechanism of resistance, ensuring that the
downstream immunomodulatory effects of
PARP inhibitors are preserved.
In recent years, many in vitro and in vivo
models have supported the use of this combi-
nation. In the preclinical setting, Wang et al.
combined niraparib with anti-PD-1/anti-PD-L1
therapy and demonstrated enhanced immune
cell infiltration, interferon-stimulated gene
expression and tumour responses, irrespective
of BRCA mutation status [34].
In BRCA1-deficient ovarian cancer mice
models, Ding et al. found that PARP inhibition
led to an anti-tumour immune response
dependent on STING pathway activation [35].
They demonstrated that olaparib increased the
number of intra-tumoural effector CD4? and
CD8? T cells, associated with increased recruit-
ment of dendritic cells, and significantly
reduced myeloid-derived suppressor cells in the
tumour tissue, spleen and blood. This response
occurred via activation of the STING pathway in
dendritic cells, mediated by sensing of tumour-
derived DNA and/or cGAMP [35]. They also
discovered increased expression of PD-L1 on
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tumour cells treated with olaparib and investi-
gated the addition of anti-PD-1 antibody. They
found that the combination treatment resulted
in sustained suppression of BRCA1-deficient
tumour cells compared with olaparib alone,
concluding that the activation of the PD-1/PD-
L1 immune-inhibitory pathway induced by
PARP inhibition can be overcome by addition of
an anti-PD-1 antibody.
A similar mechanism of immunomodulation
by PARP inhibition has been demonstrated in
other tumour types. In BRCA1-deficient models
of triple-negative breast cancer, Pantelidou et al.
demonstrated the stimulation by PARPi of
CD8? T cell recruitment mediated via the
cGAS/STING pathway in tumour cells, again
through activation of host dendritic cells [36].
These studies suggest that in the context of
HR deficiency, PARP inhibitor-mediated DNA
damage can stimulate the STING pathway,
converting immunologically cold tumours into
hot tumours, providing a good rationale for
combining PARPi with immunotherapy.
The TOPACIO trial was a phase 1/2 study
evaluating the combination of niraparib and
pembrolizumab in patients with metastatic tri-
ple-negative breast cancer and platinum-resis-
tant ovarian cancer [37]. Sixty-two patients with
ovarian carcinoma were enrolled in phases 1
and 2. The population was diverse with the
majority of patients having BRCAwt tumours
which were platinum-resistant or platinum-re-
fractory and previous treatment with beva-
cizumab. Five percent of these 62 patients had a
Fig. 6 Schematic depicting activation of cGAS/STING
pathway by PARP inhibition, leading to downstream type
1 interferon production resulting in a direct immunosup-
pressive effect by the cancer cell, as well as increased natural
killer (NK) cell and CD8 cytotoxic T cell activity causing
direct anti-tumour killing. IFN interferon, TBK-1 tank-
binding kinase 1, interferon regulatory factor 3, APC
antigen-presenting cell
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CR, 13% a PR and 47% stabilisation of disease.
In the efficacy evaluable population (n = 60),
the overall response rate was 18% (90% CI,
11–29%) and results were similar across the
HRD-negative and HRD-positive populations.
This response rate is higher than that of patients
with BRCAwt and platinum-resistant/refractory
disease treated with either single agent PARP
inhibitor or single-agent PD-1/PD-L1 inhibitor.
Combinations of Multiple Agents
In addition to combining PARPi with beva-
cizumab and PARPi with immunotherapy, there
are now studies underway investigating the
combination of all three. Preliminary results
from the phase 2 OPAL study, which is exam-
ining niraparib, bevacizumab and the PD-1
antagonist dostarlimab in recurrent, platinum-
resistant ovarian cancer, were recently
announced at SGO 2021 [38]. Forty-one
patients with advanced, recurrent ovarian, fal-
lopian tube or peritoneal cancer were enrolled,
39 of whom were radiologically evaluable. A
post hoc analysis for biomarker status revealed
that 82.9% of patients were BRCAwt, 75.6%
HRD, 68.3% PD-L1-positive and 43.9% plat-
inum-resistant. The primary end point was
objective response rate, which was 17.9%, with
seven PRs and no CRs. Twenty-three patients
had stable disease, and the overall disease con-
trol rate was 76.9%. The median PFS was
7.6 months, and no correlation with biomarker
status was seen.
Table 5 presents a list of phase 2/3 clinical
trials which are employing the combination of
niraparib with other agents in advanced/meta-
static epithelial ovarian cancer, and are cur-
rently recruiting or have recently completed
enrolment, updated as of May 2021 (search
terms ‘‘Ovarian Cancer’’ and ‘‘Niraparib’’ on
ClinicalTrials.gov).
DISCUSSION
It is likely that the treatment options for
patients with advanced ovarian cancer will
continue to expand, with several trials under-
way exploring different combinations. The best
approach will therefore be with individualised
treatment regimens to ensure optimum therapy
for each patient at the appropriate time. With
PARPi licensed in both the front-line and
recurrent setting, the decision will need to be
made regarding maximising treatment up front
or adopting a sequential use of targeted thera-
pies. The concern with ‘saving’ PARPi for later
use in the recurrent setting is that patients will
need to demonstrate a second response to
platinum-based therapy in order to be eligible,
and therefore the opportunity to use PARP
inhibition may be lost.
Characterising patients in terms of
biomarkers and high-risk features can help with
the treatment decision-making process. How-
ever, the genomic complexity of epithelial
ovarian cancer and the limitations of HRD
testing as discussed above have precluded the
development of the ultimate biomarker for
treatment selection. Establishing a standardised
platform for germline testing and tumour
sequencing that adequately detects genomic
instability to define HRD is essential if it is to be
used as a predictive biomarker to guide
treatment.
For patients with the BRCA mutation, argu-
ably the best currently licensed up-front treat-
ment is PARP inhibition alone, as these patients
are likely to respond very well. Preclinical
studies suggest that patients with gBRCA
mutations (gBRCA1/2m) have more immuno-
logically inflamed tumours as compared to
patients with HRP epithelial ovarian carcinomas
[39–41]. Patients with gBRCA1/2m may also
have fewer immunosuppressive myeloid-
derived suppressor cells and more peripheral
CD8? T cells compared to their BRCAwt coun-
terparts. This immune phenotype represents a
rich immunological potential that can be har-
nessed to produce more durable responses.
Niraparib, alongside other PARPi, has the
potential to activate interferon signalling and
enhance tumour neo-antigen presentation to
resident tumour infiltration lymphocytes in
order to induce immunogenic cell death. Direct
STING agonists have been evaluated in the
preclinical setting in combination with PARPi.
Preliminary in vitro experiments [26, 42] of this
combination in BRCA-deficient breast cancer
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models demonstrated that PARP inhibition and
STING agonism can augment STING pathway
activation and pro-inflammatory cytokine pro-
duction along with improved leucocyte and
dendritic cell function compared to monother-
apy. Clinical evaluation of direct STING ago-
nism with PARP inhibition is not yet underway,
but this is likely to change very soon.
Patients with HRD who are BRCAwt are still
likely to experience a good response to PARP
inhibition, and monotherapy with niraparib is a
reasonable option, especially for those with no
residual macroscopic disease post surgery. For
those with high-risk features, the addition of
bevacizumab to PARPi should be considered,
and the combination of olaparib and beva-
cizumab is licensed in this setting on the basis
of the PAOLA-1 trial. There has been no ran-
domised phase 3 trial assessing niraparib with
bevacizumab, but the preliminary data from
OVARIO are encouraging for this combination
as well.
For HRP patients, niraparib monotherapy is
currently licensed but is unlikely to be sufficient
alone, and combination with bevacizumab is
likely to offer the most benefit for these
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patients. In the absence of HRD, platinum sen-
sitivity can be used as a surrogate predictive
biomarker for the use of PARP inhibition as well
as the presence of high-risk features, as reflected
by the patient population in PRIMA. For those
with HRP disease who respond less well to
platinum-based chemotherapy, perhaps beva-
cizumab monotherapy should be considered.
To date we have no direct comparison from
randomised trials comparing maintenance
PARPi with maintenance bevacizumab for plat-
inum-sensitive ovarian cancer. A network meta-
analysis of 13 trials (one of which was the
NOVA study) involving patients with platinum-
sensitive recurrent ovarian cancer treated with
PARPi or bevacizumab was published last year
[43]. These indirect comparisons suggest
improved PFS with PARPi compared to beva-
cizumab, although subgroup analyses indicate
that the superiority does not reach statistical
significance in the BRCAwt population. Even in
this subgroup, however, PARPi maintenance did
have the highest likelihood of being ranked as
the best treatment according to the surface
under the cumulative ranking curve (SUCRA)
value. The group therefore concluded that
PARPi should be the preferred choice for
patients with recurrent platinum-sensitive
ovarian cancer. It is important to note that
because PARPi are being increasingly used in the
first-line setting, we have less knowledge of the
role of PARPi for recurrent disease in patients
who have already received PARPi up front.
Further research is required to assess the efficacy
of retreatment with PARPi following relapse.
It is clear that niraparib and other PARPi will
continue to play a crucial role in the manage-
ment of patients with platinum-sensitive
epithelial ovarian cancer in both the up-front
and recurrent setting, regardless of HR status.
Ongoing research is required to improve the
outcomes for patients with platinum-resistant
disease, as well as to accurately identify a pre-
dictive biomarker for PARP inhibition and to
maximise the benefit of these agents through
combination with other targeted treatments.
ACKNOWLEDGEMENTS
Figures 1, 4, 5 and 6 are original figures created
using Biorender.com.
Funding. No funding or sponsorship was
received for this study or publication of this
article. However, Rami Mustapha and Kenrick
Ng are currently research fellows funded by
Cancer Research UK, under Award Numbers
C604/A25135 and C1519/28682 (support of
R.M.) and 549580 (support of K.N.).
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published.
Authorship Contributions. Ionut-Gabriel
Funingana, Melek Akay, Kenrick Ng and
Michael Flynn conceived and designed the
review. Melek Akay, Grisma Patel, Rami Musta-
pha, Ernese Gjafa, Tony Ng and Kenrick Ng
drafted and revised the manuscript. Tony Ng
and Michael Flynn provided supervision of this
manuscript. All authors agreed on the final
version of the manuscript to be published.
Disclosures. Tony Ng has received research
funding from Astrazeneca and Daichii Sankyo.
Kenrick Ng has received honoraria from GSK/
Tesaro, Pfizer and Boehringer Ingelheim and
travel expenses from GSK/Tesaro. Michael
Flynn has received honoraria from GSK. Ionut
Gabriel Funingana has received travel expenses
from GSK/TESARO. The other authors declare
no conflicts of interests.
Compliance with Ethics Guidelines. This
article is based on previously conducted studies
and does not contain any studies with human
participants or animals performed by any of the
authors.
Data Availability. Data sharing is not
applicable to this article as no data sets were
generated or analysed during the current study.
Oncol Ther (2021) 9:347–364 361
Open Access. This article is licensed under a
Creative Commons Attribution-NonCommer-
cial 4.0 International License, which permits
any non-commercial use, sharing, adaptation,
distribution and reproduction in any medium
or format, as long as you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons licence, and
indicate if changes were made. The images or
other third party material in this article are
included in the article’s Creative Commons
licence, unless indicated otherwise in a credit
line to the material. If material is not included
in the article’s Creative Commons licence and
your intended use is not permitted by statutory
regulation or exceeds the permitted use, you
will need to obtain permission directly from the




1. Hoeijmakers JH. Genome maintenance mecha-
nisms for preventing cancer. Nature.
2001;411(6835):366–74.
2. Lord CJ, Ashworth A. PARP inhibitors: Synthetic
lethality in the clinic. Science. 2017;355(6330):
1152–8.
3. Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1,
PARP-2 and ATM in the DNA damage response:
functional synergy in mouse development. DNA
Repair (Amst). 2004;3(8–9):1103–8.
4. Hopkins TA, Ainsworth WB, Ellis PA, et al. PARP1
Trapping by PARP Inhibitors Drives Cytotoxicity in
Both Cancer Cells and Healthy Bone Marrow. Mol
Cancer Res. 2019;17(2):409–19.
5. Nijman SM, Friend SH. Potential of the synthetic
lethality principle. Science. 2013;342(6160):
809–11.
6. Sandhu SK, Schelman WR, Wilding G, et al. The
poly(ADP-ribose) polymerase inhibitor niraparib
(MK4827) in BRCA mutation carriers and patients
with sporadic cancer: a phase 1 dose-escalation
trial. Lancet Oncol. 2013;14(9):882–92.
7. Jones P, Altamura S, Boueres J, et al. Discovery of
2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-car-
boxamide (MK-4827): a novel oral poly(ADP-
ribose)polymerase (PARP) inhibitor efficacious in
BRCA-1 and -2 mutant tumors. J Med Chem.
2009;52(22):7170–85.
8. Jones P, Wilcoxen K, Rowley M, Toniatti C. Nira-
parib: A Poly(ADP-ribose) Polymerase (PARP) Inhi-
bitor for the Treatment of Tumors with Defective
Homologous Recombination. J Med Chem.
2015;58(8):3302–14.
9. Mikule KWK. Abstract B168: The PARP inhibitor
niraparib crosses the blood brain barrier in rodents
and is efficacious in a BRCA2 mutant intracranial
tumor model. Mol Cancer Ther. 2015;14(12):168.
10. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib
Maintenance Therapy in Platinum-Sensitive,
Recurrent Ovarian Cancer. N Engl J Med.
2016;375(22):2154–64.
11. Mirza MR, Benigno B, Dørum A, et al. Long-term
safety in patients with recurrent ovarian cancer
treated with niraparib versus placebo: Results from
the phase III ENGOT-OV16/NOVA trial. Gynecol
Oncol. 2020;159(2):442–8.
12. LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.
Exploring and comparing adverse events between
PARP inhibitors. Lancet Oncol. 2019;20(1):e15–28.
13. Berek JS, Matulonis UA, Peen U, et al. Safety and
dose modification for patients receiving niraparib.
Ann Oncol. 2018;29(8):1784–92.
14. Oza AM, Matulonis UA, Malander S, et al. Quality of
life in patients with recurrent ovarian cancer trea-
ted with niraparib versus placebo (ENGOT-OV16/
NOVA): results from a double-blind, phase 3, ran-
domised controlled trial. Lancet Oncol. 2018;19(8):
1117–25.
15. Gonzalez-Martin A, Pothuri B, Vergote I, et al.
Niraparib in Patients with Newly Diagnosed
Advanced Ovarian Cancer. N Engl J Med.
2019;381(25):2391–402.
16. Moore KN, Secord AA, Geller MA, et al. Niraparib
monotherapy for late-line treatment of ovarian
cancer (QUADRA): a multicentre, open-label, sin-
gle-arm, phase 2 trial. Lancet Oncol. 2019;20(5):
636–48.
17. Telli ML, Timms KM, Reid J, et al. Homologous
Recombination Deficiency (HRD) Score Predicts
Response to Platinum-Containing Neoadjuvant
Chemotherapy in Patients with Triple-Negative
Breast Cancer. Clin Cancer Res. 2016;22(15):
3764–73.
18. Miller RE, Leary A, Scott CL, et al. ESMO recom-
mendations on predictive biomarker testing for
homologous recombination deficiency and PARP
362 Oncol Ther (2021) 9:347–364
inhibitor benefit in ovarian cancer. Ann Oncol.
2020;31(12):1606–22.
19. Burger RA, Brady MF, Bookman MA, et al. Incor-
poration of bevacizumab in the primary treatment
of ovarian cancer. N Engl J Med. 2011;365(26):
2473–83.
20. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial
of bevacizumab in ovarian cancer. N Engl J Med.
2011;365(26):2484–96.
21. Elaimy AL, Amante JJ, Zhu LJ, et al. The VEGF
receptor neuropilin 2 promotes homologous
recombination by stimulating YAP/TAZ-mediated
Rad51 expression. Proc Natl Acad Sci U S A.
2019;116(28):14174–80.
22. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib
plus Bevacizumab as First-Line Maintenance in
Ovarian Cancer. N Engl J Med. 2019;381(25):
2416–28.
23. Mirza MR, Avall Lundqvist E, Birrer MJ, et al. Nira-
parib plus bevacizumab versus niraparib alone for
platinum-sensitive recurrent ovarian cancer
(NSGO-AVANOVA2/ENGOT-ov24): a randomised,
phase 2, superiority trial. Lancet Oncol.
2019;20(10):1409–19.
24. Hardesty MM KT, Wright GS et al. Phase 2 OVARIO
study of niraparib plus bevacizumab therapy in
advanced ovarian cancer following frontline plat-
inum-base chemotherapy with bevacizumab. Soci-
ety of Gynecologic Oncology Virtual Annual
Meeting on Women’s Cancer. 2021.
25. Borella F, Ghisoni E, Giannone G, et al. Immune
Checkpoint Inhibitors in Epithelial Ovarian Can-
cer: An Overview on Efficacy and Future Perspec-
tives. Diagnostics (Basel). 2020;10(3):146.
26. Constantia Pantelidou HJ, Aditi Kothari, Renyan
Liu, Jennifer L. Guerriero, Geoffrey I. Shapiro.
STING agonism enhances anti-tumor immune
responses and therapeutic efficacy of PARP inhibi-
tion in BRCA-associated breast cancer. bioRxiv.
2021.
27. Du H, Xu T, Cui M. cGAS-STING signaling in cancer
immunity and immunotherapy. Biomed Pharma-
cother. 2021;133:110972.
28. Kim C, Wang XD, Yu Y. PARP1 inhibitors trigger
innate immunity via PARP1 trapping-induced DNA
damage response. Elife. 2020;9:e60637.
29. Zheng J, Mo J, Zhu T, et al. Comprehensive elabo-
ration of the cGAS-STING signaling axis in cancer
development and immunotherapy. Mol Cancer.
2020;19(1):133.
30. Kwon J, Bakhoum SF. The Cytosolic DNA-Sensing
cGAS-STING Pathway in Cancer. Cancer Discov.
2020;10(1):26–39.
31. Kitai Y, Kawasaki T, Sueyoshi T, et al. DNA-con-
taining exosomes derived from cancer cells treated
with topotecan activate a STING-dependent path-
way and reinforce antitumor immunity. J Im-
munol. 2017;198(4):1649–59.
32. Ablasser A, Schmid-Burgk JL, Hemmerling I, et al.
Cell intrinsic immunity spreads to bystander cells
via the intercellular transfer of cGAMP. Nature.
2013;503(7477):530–4.
33. Jiao S, Xia W, Yamaguchi H, et al. PARP Inhibitor
Upregulates PD-L1 Expression and Enhances Can-
cer-Associated Immunosuppression. Clin Cancer
Res. 2017;23(14):3711–20.
34. Wang Z, Sun K, Xiao Y, et al. Niraparib activates
interferon signaling and potentiates anti-PD-1
antibody efficacy in tumor models. Sci Rep.
2019;9(1):1853.
35. Ding L, Kim HJ, Wang Q, et al. PARP inhibition
elicits STING-dependent antitumor immunity in
Brca1-deficient ovarian cancer. Cell Rep.
2018;25(11):2972-2980 e2975.
36. Pantelidou C, Sonzogni O, De Oliveria TM, et al.
PARP Inhibitor Efficacy Depends on CD8(?) T-cell
Recruitment via Intratumoral STING Pathway
Activation in BRCA-Deficient Models of Triple-
Negative Breast Cancer. Cancer Discov. 2019;9(6):
722–37.
37. Konstantinopoulos PA, Waggoner S, Vidal GA, et al.
Single-Arm Phases 1 and 2 Trial of Niraparib in
Combination With Pembrolizumab in Patients
With Recurrent Platinum-Resistant Ovarian Carci-
noma. JAMA Oncol. 2019;5(8):1141–9.
38. Liu JF GS, Wahner Hendrickson AE, et al. An open-
label phase II study of dostarlimab (TSR-042),
bevacizumab (bev), and niraparib combination in
patients (pts) with platinum-resistant ovarian can-
cer (PROC): Cohort A of the OPAL trial. Society of
Gynecologic Oncology 2021 Virtual Annual Meet-
ing on Women’s Cancer. March 2021.
39. Koti M, Siu A, Clément I, et al. A distinct pre-ex-
isting inflammatory tumour microenvironment is
associated with chemotherapy resistance in high-
grade serous epithelial ovarian cancer. Br J Cancer.
2015;112(7):1215–22.
40. Xu H, Xian J, Vire E, et al. Up-regulation of the
interferon-related genes in BRCA2 knockout
epithelial cells. J Pathol. 2014;234(3):386–97.
Oncol Ther (2021) 9:347–364 363
41. Strickland KC, Howitt BE, Shukla SA, et al. Associ-
ation and prognostic significance of BRCA1/2-mu-
tation status with neoantigen load, number of
tumor-infiltrating lymphocytes and expression of
PD-1/PD-L1 in high grade serous ovarian cancer.
Oncotarget. 2016;7(12):13587–98.
42. Jeyasekharan AD. PARP inhibitors need an extra
STING for therapeutic efficacy. Sci Transl Med.
2019;11(494).
43. Bartoletti M, Pelizzari G, Gerratana L, et al. Beva-
cizumab or PARP-inhibitors maintenance therapy
for platinum-sensitive recurrent ovarian cancer: a
network meta-analysis. Int J Mol Sci. 2020;21(11).
364 Oncol Ther (2021) 9:347–364
